Trial Profile
Safety of tenofovir alafenamide (TAF) in patients with a history of tubulopathy on tenofovir disoproxil fumarate (TDF)
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Emtricitabine/tenofovir alafenamide (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- Acronyms FANCONI-TAF (FANTA) study
- 14 Sep 2021 Results(n=31) assessing Safety of Tenofovir Alafenamide in People With HIV Who Experienced Proximal Renal Tubulopathy on Tenofovir Disoproxil Fumarate published in the JAIDS
- 10 Mar 2021 Results (n=31) assessing safety of tenofovir alafenamide with a history of Proximal Renal Tubulopathy while receiving TDF, presented at the 28th Conference on Retroviruses and Opportunistic Infections
- 12 Apr 2017 New trial record